Arcus Biosciences Inc (NYSE:RCUS) Director Kathryn E. Falberg Acquires 20,000 Shares

Arcus Biosciences Inc (NYSE:RCUS) Director Kathryn E. Falberg bought 20,000 shares of the stock in a transaction on Wednesday, June 12th. The stock was purchased at an average price of $8.20 per share, for a total transaction of $164,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of NYSE:RCUS traded down $0.26 during midday trading on Friday, reaching $8.28. 13,177 shares of the company traded hands, compared to its average volume of 139,363. Arcus Biosciences Inc has a 12 month low of $7.40 and a 12 month high of $17.18. The firm has a market cap of $369.20 million, a price-to-earnings ratio of -5.79 and a beta of 1.22.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). Arcus Biosciences had a negative net margin of 613.46% and a negative return on equity of 22.72%. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $1.25 million. On average, sell-side analysts predict that Arcus Biosciences Inc will post -1.64 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in RCUS. Svennilson Peter bought a new stake in shares of Arcus Biosciences during the 4th quarter valued at $38,135,000. BlackRock Inc. grew its position in Arcus Biosciences by 295.5% during the fourth quarter. BlackRock Inc. now owns 1,721,894 shares of the company’s stock worth $18,545,000 after buying an additional 1,286,470 shares in the last quarter. Aisling Capital Management LP purchased a new position in Arcus Biosciences during the fourth quarter worth about $5,778,000. Hillhouse Capital Advisors Ltd. purchased a new position in Arcus Biosciences during the fourth quarter worth about $4,577,000. Finally, BVF Inc. IL grew its position in Arcus Biosciences by 16.5% during the first quarter. BVF Inc. IL now owns 2,810,223 shares of the company’s stock worth $35,100,000 after buying an additional 398,600 shares in the last quarter. Institutional investors own 46.58% of the company’s stock.

A number of analysts recently issued reports on the company. Citigroup decreased their price objective on Arcus Biosciences from $25.00 to $15.00 and set an “in-line” rating on the stock in a research note on Wednesday, June 5th. Zacks Investment Research lowered Arcus Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Svb Leerink reiterated an “outperform” rating on shares of Arcus Biosciences in a research note on Friday, May 3rd. Finally, BTIG Research assumed coverage on Arcus Biosciences in a research note on Monday, March 18th. They set a “buy” rating and a $20.00 price objective on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.50.

COPYRIGHT VIOLATION WARNING: This report was first reported by Stock Observer and is owned by of Stock Observer. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thestockobserver.com/2019/06/14/arcus-biosciences-inc-nysercus-director-kathryn-e-falberg-acquires-20000-shares.html.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

See Also: How Short Selling Works

Insider Buying and Selling by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.